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Abstract
Background and Aim: Nonadherence to antihypertensive medication impairs optimal
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blood pressure and is influenced by multiple interrelating factors. Knowing the
complexity of medication nonadherence and its associated factors is essential for
intervention strategies. This study evaluated the predictors of medication
nonadherence among hypertensive clients in a Ghanaian population.
Methods: This was a hospital‐based cross‐sectional study conducted at the
Hypertensive Clinic of the Kwame Nkrumah University of Science and Technology
(KNUST) Hospital, Kumasi, Ghana. A self‐designed questionnaire, the Hill‐Bone
Compliance to High Blood Pressure Therapy and Perceived Barriers to Treatment
Compliance Scales, were used for data collection from 246 hypertensives. Data were
analyzed using Statistical Package for Social Sciences, version 25.
Results: Medication nonadherence was observed among 8.5% of the study
participants. In a multivariate regression model perceived noneffectiveness of
medication (odds ratio [OR] = 1.76, 95% confidence interval [CI]: 1.34–2.31,
p < 0.001) and barriers to alcohol and smoking cessation (OR = 2.83, 95% CI:
1.31–6.13, p = 0.008) were associated increased odds of antihypertensive medica-
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tion nonadherence. Also, patients who do not know their total prescription
(OR = 8.81, 95% CI: 2.28–34.0, p = 0.002) were more likely to be nonadherent to
their antihypertensive medications. Moreover, clients who associate signs/symptoms of palpitations (OR = 5.82, 95% CI: 1.31–25.80, p = 0.021), poor sleep
(OR = 3.92, 95% CI: 1.09–14.12, p = 0.036) and decreased sexual drive (OR = 4.74,
95% CI: 0.96–23.28, p = 0.055), were more likely to be nonadherent to
antihypertensive medication.
Conclusion: In conclusion, we observed a lower nonadherence rate among
hypertensive clients in a Ghanaian population with correlates being medication‐
related factors. Most importantly, perceived noneffectiveness of medication,
barriers to smoking and alcohol cessation, palpitations, poor sleep, and decreased
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sexual drive significantly predicted lower adherence and could serve as indicators for
high risk of nonadherence to antihypertensive medications.
KEYWORDS

antihypertensives, Hill‐Bone, hypertension, nonadherence, perceived barriers
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| INTRODUCTION

alliance in which clients' doubts and difficulties with therapy can be
detected and addressed. This study used Hill‐Bone Therapy Compliance

Hypertension (HPT) represents global crises and a single risk factor

and Perceived Barriers to Treatment Compliance Scales to evaluate

for cardiovascular diseases. The World Health Organization (WHO)

medication nonadherence and its correlates among hypertensive clients

2019 fact‐sheet indicated that an estimated 1.13 billion people

in a Ghanaian population.

worldwide have HPT, with two‐thirds living in low‐ and middle‐
income countries (LMIC).1 This figure represents a global increase
burden of HPT. Africa shares about 46% of all HPT mortality in

2 |
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LMIC.2 In Ghana, the prevalence rates of HPT range from
19.2%–32.8% in the rural population to 25.5%–48.0% in urban

2.1 |

Study design/site

centers. HPT was the highest represented disease in the Ghana
Health Service 2014 Annual report, between 2011 and 2014. The

The study used a descriptive cross‐sectional study design. It was

Ashanti region recorded the second‐highest number of new

conducted at the Kwame Nkrumah University of Science and

outpatient hypertensive cases (140,947) diagnosed simultaneously.2

Technology (KNUST) Hospital, Kumasi, Ghana. It is a University

More recently, less than half of hypertensive clients in Ghana are

Hospital located on the premises of KNUST, in the Oforikrom

aware of their hypertensive status.3

constituency and municipality. In line with the determination of the

With the constantly alarming figures of HPT in general and

hospital to provide effective and accessible healthcare services to its

especially in Ghana, common behavioral changes represent a low‐

clients, the KNUST Hospital established the HPT Clinic, which

cost alternative for prevention. Besides, among those living with

commenced its activities on May 30, 2008. The main aim of the clinic

HPT, diagnosis, initiation, and retention to care and adherence to

is for the efficient management of HPT to improve their quality of life

both pharmacological and nonpharmacological therapy are essential

and prevent or reduce complications in these clients. The clinic has

4

for reducing consequent cardiovascular complications.

Notwith-

about 600 registered hypertensives as clients.

standing the existence of vast evidence on the advantages of HPT
treatment, control of blood pressure (BP) has been disappointing.
Various studies have reported that BP control among hypertensive
clients in Ghana is mainly poor due to noncompliance to therapy.

2.2 |

Eligibility criteria

5

Previous studies have established the high prevalence of uncon-

Participants who had been diagnosed with HPT and are on treatment

trolled HPT in Ghana,2,6,7 however, there is limited data on correlates

for at least 6 months attending the hypertensive clinic of KNUST

that influence HPT control in the Ghanaian hypertensive popula-

Hospital and gave written consent were recruited into the study.

tion.3,5 Thus, assessing medication adherence and its correlates is

Clients who have been on treatment for less than 6 months were

vital to ascertain and monitor treatment and its outcomes to reduce

excluded from the study. Also, clients who were transferred in or not

HPT‐related mortality.

registered at the KNUST hospital for regular appointment schedules

It is essential to admit that addressing medication adherence is

were excluded from the study. Clients who had confirmed

essential and disreputably difficult in practice. Sometimes, clients are

comorbidities such as diabetes mellitus, heart diseases, renal diseases

unable to give accurate reports of their adherence to medication. It has

were also excluded.

been shown that less than 50% of hypertensive patients that are
initiated to care, take their medications as prescribed.3,8 To‐wit
interviewing clients using questinnaires represents a powerful tool for

2.3 |

Sample size justification

ascertaining clients' concepts and behavior regarding medication
adherence. These tools represent an easy‐to‐use, low‐cost subjective

The sample size for this study was calculated using the formula

method to survey clients' medication‐taking behavior and possible

described by Charan and Biswas.10 Using 58.6% as the rate of

factors that influence their decision. They are designed to standardize

noncompliance to antihypertensive treatment from our previous

and minimize the limitations of other self‐reported adherence measure-

study,3 with a standard normal variate of 1.96 (at 5% type‐1 error),

9

ment methods to a specific medication regime. Thus, providing basic

0.05 precision and 65% response rate, the least estimated sample

information that helps optimize treatment and form a therapeutic

size for the study was 242 from a total estimated population of 600
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clients over 6 months period. Accordingly, a sample size of 246 was
finally used.

2.5.3 |
Scale
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Perceived Barriers to Therapy Compliance

The questionnaire consisted of nine items that assessed perceived

2.4

| Data collection

barriers to medication adherence. The questionnaire was designed to
assess four domains of medication nonadherence; perceived benefits

Data were collected from September 2018 to February 2019.

of medication (three items), barriers to medicine accessibility (two

Participants were recruited using the convenient sampling method.

items), barriers to lifestyle and dietary practices (two items) as well as

Depending on the total number of clients per clinic, a range of 15–22

barriers to alcohol and smoking cessation (two items). The reliability

clients were conveniently sampled weekly for the entire 6 months.

of the scale ranged from 0.621 to 0.800 (Table S2).

Hypertensive clients who did not consent or were seriously ill (too
sick to be interviewed) were excluded from the study. For all included
participants, a questionnaire interview was conducted using a

2.6 |

Ethical consideration and informed consent

structured close‐ended questionnaire to collect data on demography,
therapy adherence, perceived barriers, and symptoms/side effects of

The Committee on Human Research approved the study, Publications

medication. The entire questionnaires were available in the English

and Ethics (CHRPE), School of Medical Sciences, Kwame Nkrumah

version but were interviewed carefully with the proper translation of

University of Science & Technology (KNUST), Kumasi (CHRPE/AP/

the official local language of the study population. The participants'

215/17) and the research committee of KNUST Hospital, Kumasi.

responses were translated back to English in the correct meaning as

Informed consent was obtained from all participants and confiden-

was interpreted.

tiality was assured.

2.5
2.5.1

| Description and validation of questionnaires
| Sociodemographic questionnaire

2.7 |

Data analysis

Data analyses were performed using SPSS v. 25. Descriptive statistics
in percentages and cross‐tabulation were used to evaluate demo-

The questionnaire consisted of items that assessed the participants'

graphic and adherence status. Inferential statistics to examine the

details and medication history. Besides, the questionnaire contained

relationships between adherence and perceived barriers to adher-

sections that evaluated medication's most frequently perceived side

ence were computed using the Spearman rank correlation and logistic

effects from the past 3 months before data collection.

regression analysis. Also, univariate and multivariate analysis was
used to examine factors associated with medication nonadherence.
All factors associated with nonadherence at a p < 0.1 were included in

2.5.2 | Hill‐Bone Compliance to High Blood
Pressure Therapy Scale

a prediction model, and the results were presented. p < 0.05 were
considered statistically significant.

This questionnaire was adapted from a previous study by Kim
et al.11 that assessed antihypertensive therapy adherence in

3 |

RESULTS

predominantly black populations. It is a 14‐items scale used to
assess patients' behaviors for three important behavioral domains of

A descriptive summary of sociodemographic and medication history

high BP treatment: (1) reduced‐sodium intake, (2) appointment

is shown in Table 1. Participants aged 50–59 years and 60–69 years

keeping, and (3) medication taking. In this study, the only influential

constituted 37% and 39% of the study sample. Also, female

factor that could be interpreted in acceptability, reliability, and

participants mainly were represented (69.5%). Also, most of the

validity analysis was the medication‐taking subscale (Table S1).

respondents have been on treatment for either 8–10 years (32.5%) or

Thus, we simplified the 14‐items Hill‐Bone Scale to an 8‐items scale

above 10 years (37.8%).

for the assessment of medication intake behavior. This eight‐

Table 2 summarizes the medication history of the study partici-

questions item is similar to the short‐form scale used by previous

pants. More than half of the respondents did not know the names of

studies.11,12 The internal consistency and reliability of the scale

their current medications. Most of the respondents were on dual

were shown by a Cronbach's α (0.763) and mean inter‐item

therapy (36.2%), followed by three‐drug treatment (27.6%). A majority

correlation (0.243) (Table S1). The total score ranged from 19 to

(69.9%) had ever forgotten to take their BP medicine. Frequently

32 (mean = 28.9797) with higher scores indicating good adherence.

perceived signs/symptoms of antihypertensive medications were head-

A value below or equal to the fifth percentile which is equivalent to

aches (26.4%), followed by muscle pain (18.3%), tiredness (11.0%),

≤80% (mean − 2SD) of the total score was used to define medication

decreased sexual desire or ability (9.8%), poor sleeping (8.5%), frequent

nonadherence.

urination (7.7%), palpitations (6.5%), and swollen feet (4.9%).

4 of 9
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T A B L E 1 Sociodemographic characteristics of the study
participants
Variable

Category

Age (years)

<50

Frequency
(N = 246)

ET AL.

subscale. Perceived noneffectiveness of medication significantly
correlated negatively with medication adherence score (ρ = −0.50,
p < 0.001). Also, barriers to alcohol and smoking cessation signifi-

Percentage (%)

cantly negatively correlated with medication adherence score

42

17.1

(ρ = −0.25, p = 0.001).

50–59

91

37.0

60–69

96

39.0

70–79

17

6.9

among the study participants (Table S3). In Table S4, total prescribed

Female

171

69.5

medication (p = 0.011) and appointment schedules (p = 0.031) were

Male

75

30.5

Single

26

10.6

188

76.4

barriers to alcohol and smoking cessation (OR = 2.26, 95% CI:

Widowed

32

13.0

1.42–3.58, p = 0.001) were associated with increased odds of

No formal
education

41

16.7

Basic School

112

45.5

High school

36

14.6

Tertiary

57

23.2

p = 0.023), poor sleep (OR = 4.08, 95% CI: 1.33–1.32, p = 0.014),
and decreased sexual desire or ability (OR = 4.60, 95% CI:

Cross‐tabulation and Fischer's Exact test are shown in Tables S3
and S4. There was no significant association observed between

Gender

sociodemographic characteristics and medication nonadherence

significantly associated with adherence status.
Perceived noneffectiveness of medication (odds ratio [OR] =

Marital Status

Married

Level of
education

1.70, 95% confidence interval [CI]: 1.41–2.05, p < 0.001) and

antihypertensive medication nonadherence. Also, clients who do
not know their total prescription were associated with significantly
increased odds of medication nonadherence (OR = 4.97, 95% CI:
1.57–15.78, p = 0.006). Moreover, clients who associate signs/

Occupation

symptoms of palpitations (OR = 4.18, 95% CI: 1.22–14.35,

Government
employee

47

19.1

Retired

43

17.5

131

53.3

25

10.2

219

89.0

dietary changes, alcohol and smoking cessation, and perceived

Muslim

27

11.0

symptoms of palpitations and muscle pain were associated with

<1

14

5.7

1–3

21

8.5

4–7

38

15.4

8–10

80

32.5

>10

93

37.8

Self‐employed

1.59–13.31, p = 0.005) to antihypertensive medication, were more
likely to be nonadherent. These associations were not attenuated
in the multivariate model.
In a hierarchy regression analysis, as shown in Table S6,

Unemployed
Religion

Duration on
treatment
(years)

Christian

perceived barriers to medication noneffectiveness, lifestyle and

lower medication adherence scores (Table 5).

4 |

D IS CU SS IO N

Medication nonadherence presents a significant limitation in combating public health challenges in both developed and developing
countries.13 It is an active decision of a patient, relatively to
misunderstandings of the condition and general disapproval of

The response frequencies for the 8‐items Hill‐Bone Medica-

medication, but mostly taken to facilitate daily life or minimize

tion Compliance subscale and Perception of Barriers to High

complications.14 On the contrary, adherence to antihypertensive

Blood Pressure (BP) Therapy Compliance Scale are listed in

medication is associated with significantly lower total healthcare cost,

Table 3. Most study participants indicated that they either forget

overall odds of reduced cardiovascular‐related hospitalizations, and

to take their medications (64.2%) or decide not to take their

lower emergency department visits.15 This study assessed the

medication (83.3%). The majority of the respondents opted for

correlates of medication adherence among hypertensive clients in a

answers “none of the time” in all domains of the Hill‐Bone

Ghanaian population. We observed that a significant percentage

subscale. The option “not at all” recorded the highest score on all

(approximately 70%) of the hypertensive clients have stopped taking

the fields of the perceived barriers on the compliance scale

their medication at least within the last 3 months. This action taken

(Figure 1).

by clients has been associated with adverse effects on the

The majority (91.5%) of the respondents were adherent to

medication‐taking behavior of clients. However, medication non-

current medications, whereas 8.5% showed some level of nonadher-

adherence was relatively lower (8.5%) among them. This finding can

ence to current medication taking

be attributed to the fact that most (74.9%) of the study participants

Table 4 shows the correlation of the Perceived Barriers to

decidedly skip their BP medicine before their scheduled appointment

Medication Adherence Scales and Hill‐Bone Medication Adherence

with the doctor. Moreover, most of the study participants indicated

WOODE
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TABLE 2

5 of 9

Medication characteristics of the study participants

Variable

Category

Frequency
(N = 246)

Percentage (%)

Knowledge of the name of current
medication use

No

133

54.1

Yes

113

45.9

Knowledge of total prescribed medication

Don't know

47

19.1

Yes (<3 medicines)

89

36.2

Yes (≥3 medicines)

110

44.7

Monotherapy

10

4.1

Fixed‐dose combination

34

13.8

Dual therapy

89

36.2

Three‐drug therapy

68

27.6

Four‐drug therapy

31

12.6

Five‐drug therapy

14

5.7

<Every 3 months

22

8.9

Every 3 months

130

52.8

Every 4 months or beyond

35

14.2

Ever forgotten to take BP medication
within the past 3 months

No

74

30.1

Yes

172

69.9

Perceived signs/symptoms of medication

No

127

51.6

Yes

119

48.4

Tiredness

27

11.0

Palpitations

16

6.5

Swollen feet

12

4.9

Muscle pain

45

18.3

Headaches

65

26.4

Poor sleeping

21

8.5

Frequent urination

19

7.7

Low libido

24

9.8

Prescription pattern

Appointment periods and blood pressure
(BP) check‐ups

Frequently perceived sign/symptom of
medication over the last 3 months

that sometimes but not always, they either forget to take their

use by this study is one of the most frequently used instruments for

medications or decide not to take their medication.

measuring high BP medication adherence.11,18 Besides, it is the best

Inconsistent with our present findings, some studies have
consistently reported a high rate of medication nonadherence among
hypertensive clients.

3,5,8,16

population.13,19,20

found that

The common theme identified as a consistent factor predictive

approximately 85% of their participants adhere to their medication

of medication nonadherence was the perceived noneffectiveness

regime. This finding suggests that adherence to antihypertensive

of antihypertensive medications. In a multivariate predictive

medication is higher than previously described in some Ghanaian

model, perceived noneffectiveness of medication and symptoms

populations.

3,5

However, Inkster et al.

17

suitable scale for studies specific to HPT in a predominantly black

This inconsistency could result from the type of

of palpitations, poor sleep, and decreased sexual desire or ability

adherence scale used and the defined cut‐off range for defining

associated with medicines were significant influencing factors of

nonadherence. For most of these scales used in various related

medication nonadherence. Grassi et al.21 have indicated that

studies,3,5,8,16 the rationale of the ranking was determined by clinical

greater than half of antihypertensive medication discontinuation

outcomes and the researcher's expertise. Thus, contributing to a wide

can be attributed to adverse effects. We observed that about 48%

range of reported inconsistencies. The advantage of this study is that

of the hypertensive clients reported on one or more perceived

the 8‐Items Hill‐Bone Medication Adherence Subscale validated for

symptoms associated with the medication. The most symptoms
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Responses for each item of the Hill‐Bone Compliance and Perception of Barriers to HBP Therapy Compliance Scales

Hill‐Bone Medication Compliance subscale (N = 246)
Items

All of
the time

Most of
the time

Some of
the time

None of
the time

How often do you forget to take your HBP medicine?

0

6.5

64.2

29.3

How often do you decide not to take your HBP medicine?

0

6.9

83.3

9.8

How often do you forget to get prescriptions filled?

1.6

2.0

27.6

68.7

How often do you run out of HBP pills?

0.4

1.2

30.9

67.5

How often do you miss taking your HBP pills when you feel better?

0.8

5.3

25.2

68.7

How often do you miss taking your HBP pills when you feel sick?

0

0

4.9

95.1

How often do you take someone else's HBP pills?

0

0

0.8

99.2

How often do you miss taking your HBP pills when you are careless?

0

0.4

11.8

87.8

74.8

15.0

5.3

4.9

How often do you skip your HBP medicine before you go to the doctor?
Perceived Barriers to Treatment Compliance Scale (N = 246)
To what extent do you think the following hinder you from complying
with your treatment?

Not at all

To some
extent

To a larger
extent

Very much
extent

Ineffectiveness of the medicine to stabilize my blood pressure

63.8

18.3

6.1

11.8

Lack of motivation because I know I cannot be cured even after taking my
medications all the time

60.2

13.8

4.1

22.0

Not having enough time to exercise

83.3

12.2

3.7

0.8

Lack of discipline to comply with the dietary restrictions

87.4

9.3

2.4

0.8

Lack of motivation to stop smoking

98.4

0.4

0.8

0.4

Easy access to alcoholic beverages

79.3

16.3

2.4

1.2

Limited financial resources

89.8

7.7

1.6

0.8

Limited access to medications and prescribed foods

93.5

5.7

0.8

0

Side effects

81.3

9.3

7.3

2.1

Note: All values are presented as percentages.
Abbreviation: HBP, high blood pressure.

lethargy, and impotence were mentioned as the most frequent
perceived symptoms of hypertensive clients.
These reported signs were associated with medication nonadherence. Gebreyohannes et al.4 reported that perceived symptoms
of tiredness, muscle pain, and poor sleep attributed to medicines are
associated with poor adherence rates. Also, Tedla and Bautista23
reported that 85% of hypertensive clients experienced side effects,
which was significantly associated with medication nonadherence.
Moreover in a systematic review and meta‐analysis by van der Laan
et al.24 and AlGhurair et al.,25 drug side effects were identified as one
of the key factors with consistent significant relationships with
medication nonadherence. Hypertensive patients frequently report
symptoms that are also reported by normotensive patients. Although
F I G U R E 1 Distribution of medication adherence among the
study participants

to a larger extent, these perceived symptoms are true for
antihypertensive medication treatment.26 A previous study has also
stated that increased specific concerns about medication can predict

reported by participants include headaches, muscle pain, tiredness,

poor adherence, which is similar to our findings.27 This finding can be

decreased sexual desire or ability, poor sleeping, frequent urina-

interpreted that, in the Ghanaian society if there is a minor ailment, a

tion, and palpitations. In a systematic review of qualitative studies

patient will just attribute it to their medications without the necessity

by Marshall et al.,22 tiredness, urinary frequency, ankle swelling,

of reporting to the healthcare provider. These perceptions can create

WOODE
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TABLE 4
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Correlation between Perceived Barriers to Medication Adherence and Hill‐Bone Medication Adherence subscale
Medication adherence score

Perceived barriers

ρ

R2 score

F change

p value

Perceived noneffectiveness of medication

−0.50

0.363

138.93

<0.001*

Barriers to medication access

−0.20

0.006

2.12

0.147

Barriers to lifestyle and dietary practices

−0.12

0.010

3.78

0.053

Barriers to alcohol and smoking cessation

−0.25

0.029

11.82

0.001*

Note: ρ = Spearman's rank correlation coefficient and R2 score = coefficient of variations. All p values with * are statistically significant.

TABLE 5

Predictors of adherence among the study participants
Univariate regression model

Multivariate regression model

N (%)

Predictors

p value

Noneffectiveness of medication

N/a

1.70 (1.41–2.05)

<0.001*

1.76 (1.34–2.31)

<0.001*

Barriers to medication access

N/a

1.40 (0.83–2.36)

0.209

1.63 (0.72–3.71)

0.241

Barriers to lifestyle and dietary changes

N/a

1.06 (0.65–1.72)

0.816

0.61 (0.25–1.47)

0.267

Barriers to alcohol and smoking cessation

N/a

2.26 (1.42–3.58)

0.001*

2.83 (1.31–6.13)

0.008*

10 (47.6)

2.24 (0.91–5.52)

0.081

0.48 (0.14–1.71)

0.259

Tiredness

3 (14.3)

1.40 (0.38–5.08)

0.613

1.53 (0.35–6.82)

0.606

Palpitations

4 (19.0)

4.18 (1.22–14.35)

0.023*

5.82 (1.31–25.80)

0.021*

Muscle pain

4 (19.0)

1.06 (0.34–3.30)

0.925

0.822 (0.22–3.07)

0.770

Headaches

7 (33.3)

1.44 (0.55–3.75)

0.455

0.66 (0.20–2.18)

0.497

Poor sleeping

5 (23.8)

4.08 (1.33–1.32)

0.014*

3.92 (1.09–14.12)

0.036*

Frequent urination

4 (19.0)

3.29 (0.98–11.03)

0.053

1.64 (0.34–7.87)

0.539

Decreased sexual desire or ability

6 (28.6)

4.60 (1.59–13.31)

0.005*

4.74 (0.96–23.28)

0.055

Don't know

9 (42.9)

4.97 (1.57–15.78)

0.006*

8.81 (2.28–34.0)

0.002*

Yes (<3 medicines)

7 (33.3)

1.79 (0.55–5.85)

0.334

2.10 (0.57–7.74)

0.262

Yes (≥3 medicines)

5 (23.8)

aOR (95% CI)

p value

Perceived barriers

Sex (male)
Perceived side effects of medication

Total prescribed medication

1 (reference)

1 (reference)

Note: All p value with * is statistically significant.
Abbreviations: CI, confidence interval; N/a, not applicable; aOR, adjusted odds ratio.

the belief that they are not worried about taking prescribed medicine

evaluated these findings.17,24 The findings of barriers to smoking and

leading to poor adherence.

alcohol cessation associated with medication nonadherence have not

The study also observed that patient sociodemographic factors

been justified. In previous unrelated clinical evaluations and

were not associated with medication adherence. In the reports of

computer‐based simulations, alcohol, and smoking affect medication

Inkster et al.,17 no significant association was reported between

adherence in both HIV‐infected and ‐noninfected clients.28,29 This

adherence to medication and sociodemographic variables, comorbid-

finding in HPT may have clinical implications concerning optimal

ities, or the number of antihypertensive drugs taken, which is partly

treatment for hypertensive clients who also smoke or consume

consistent and partly inconsistent with our findings. We also

alcohol. Thus, better knowledge about HPT and its management and

observed that barriers to smoking and alcohol cessation and not

clients' perceived benefits of medication could contribute to better

knowing total prescribed medications were associated with medica-

adherence.

tion nonadherence. The total number of medications taken by the

The study has a limitation with a small sample size which had an

patient was not associated with adherence. Some studies have partly

effect on the statistical power of the regression model performed.
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Also, the Hill‐Bone Scale for measuring adherence to medication was
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